Science and Law
27th November 2012

Biologics and Biosimilars: Focus of Future Litigation – Dr. Steven Weisman of ISS presents at ABA Litigation Meeting

I was recently invited to be part of a panel on the role of biopharmaceuticals in product liability litigation as part of ABA’s section on Litigation held in Boston: Current Issues in Pharmaceutical and Medical Device Litigation.

Biologics and Biosimilars: Focus of Future Litigation – Dr. Steven Weisman of ISS presents at ABA Litigation Meeting

I was recently invited to be part of a panel on the role of biopharmaceuticals in product liability litigation as part of ABA’s section on Litigation held in Boston: Current Issues in Pharmaceutical and Medical Device Litigation. The panel was moderated by Debra Perry of McCarter and English and my co-presenters were Krista Cosner of Drinker Biddle & Reath and and Maureen Bresnahan, in house counsel at Eisai, Inc.

Unlike traditional small molecule pharmaceuticals, biologics (including biosimilars) are large molecules, typically injected into the system that generally interact with the body in the blood stream or on the surface of cells. My presentation focused on the regulatory status of biopharmaceuticals as well their drug development, manufacturing and marketing challenges. Key amongst these are definitions of “similarity” and “interchangeability”. The simple rules followed for introduction and defense of generic “small molecule” drugs, including preemption, will no longer be valid. Planning during product development for future litigation risk is good business.

We believe that biosimilars will provide unique and complex challenges for product liability and regulatory lawyers in the years and decades to come.

Did you like this post? We are here to help! Schedule a consult with one of our experts.

Just fill out the form bellow and we will contact you with more information.

  • This field is for validation purposes and should be left unchanged.

Recent Related Articles

Dr. David Schwartz’s IADC Presentation: The Use of Genetic Testing in the Courtroom [Download Slides]
15 July 2020
Dr. David Schwartz’s IADC Presentation: The Use of Genetic Testing in the Courtroom [Download Slides]

On Wednesday July 8, 2020, Dr. David Schwartz of Innovative Science Solutions presented at the IADC 2020 Virtual Annual Meeting on a panel titled The Use of Genetic Testing in the Courtroom. A complimentary copy of the panel presentation is now available for download. Read more

The Use of Genetic Testing in the Courtroom: Dr. David Schwartz will be Presenting at the IADC 2020 Virtual Annual Meeting
02 July 2020
The Use of Genetic Testing in the Courtroom: Dr. David Schwartz will be Presenting at the IADC 2020 Virtual Annual Meeting

Dr. David Schwartz of Innovative Science Solutions will be presenting at the IADC 2020 Virtual Annual Meeting on a panel titled The Use of Genetic Testing in the Courtroom. Read more

WEBINAR ANNOUNCEMENT: What’s in Those Genes?
12 June 2020
WEBINAR ANNOUNCEMENT: What’s in Those Genes?

Genetic Evidence Concerning Causation for Mesothelioma 16 June 2020 at 2pm Eastern Daylight Time. Read more

Talc and Asbestos Defendants Should Monitor and Utilize Published Studies Linking Mesothelioma to Genomic Causes
28 April 2020
Talc and Asbestos Defendants Should Monitor and Utilize Published Studies Linking Mesothelioma to Genomic Causes

Plaintiff experts having been asserting for decades that all mesotheliomas must be linked to some asbestos exposure. Indeed, this has led to the erroneous (but widespread) view that mesothelioma is a signature disease, only caused by asbestos exposure. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us